At the IGTP TODAY
Researchers from B·ARGO and the Urological Tumour Unit at IGTP and ICO have led a study proposing a new therapeutic strategy based on a combination of kinase inhibitors for metastatic prostate cancer patients who have progressed on standard treatment. The study has been published in the journal Frontiers in Pharmacology.
A collaborative study led by researchers from IGTP has revealed the promising possibilities of using an agarose spot migration assay to examine the ability of extracellular vesicles to attract other cells in a controlled environment. The study has been recently published in the journal BMC Biology.
The collaborative project InMaM, part of the Complementary Plan for Biotechnology Applied to Health, involving both Catalonia and the Basque Country, aims to discover new immunotherapy-based treatments for metastatic breast cancer.
A new lung cancer treatment has allowed 36.8% of patients to achieve complete tumour disappearance, compared to the 6.9% rate of the standard post-surgery treatment. In addition, 85% of patients survive two years after receiving chemo-immunotherapy before surgery compared to 63% who receive chemotherapy alone before surgery. The study involved oncologist from ICO Badalona and IGTP researcher, Teresa Morán.
Retreatment with platinum-based chemotherapy as a therapy for relapsed ovarian cancer after progression to PARP inhibitors shows different results for patients with BRCA-mutated and BRCA wild-type tumours.
CARE, the Translational Program in Cancer Research is the first transversal program promoted by the Germans Trias i Pujol Research Institute (IGTP), and it aims to become a bridge for researchers in the field of cancer who want to bring basic and clinical research together, so that the knowledge and the tools generated in the laboratory can benefit the patient.
On 11-12 November the IV Workshop on translational research on urological tumours: from the laboratory to clinical practice took place at the Badalona Conference Centre (BCIN). They were jointly organized by the Germans Trias i Pujol Research Institute (IGTP) and the Badalona Applied Research Group in Oncology (B·ARGO), and the Institut Català d'Oncologia (ICO) and are scientifically accredited by SEOM and SOGUG.
A consortium led by Dr Carmen Balaña of the Badalona Applied Research Group in Oncology (B-ARGO Group) of the Catalan Institute of Oncology (ICO) Badalona at the Germans Trias i Pujol Research Institute (IGTP) has published two papers that indicate better ways to stratify glioblastoma patients, which could allow doctors to make predictions about prognosis and make better decisions about which treatments to apply.
Researchers from the IGTP, ICO and IDIBELL have observed that advanced prostate cancer cells that have become resistant to standard treatment have an Achilles heel that can be attacked with a combination of chemotherapies .
Validation of this cellular mechanism would permit identification of patients who have developed resistance to standard treatments and the implementation of more personalized medicine for prostate cancer.
